Fate Therapeutics Inc
FATE0.956USD
-0.007-0.76%
Cierre 09/15, 16:00（ET）Cotizaciones retrasadas 15 min
109.59MCap. mercado
PérdidaP/E TTM
Más Datos de Fate Therapeutics Inc Compañía
Fate Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is dedicated to bringing a pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune disorders. Its proprietary induced pluripotent stem cells (iPSC) product platform combines multiplexed-engineering of human iPSCs with single-cell selection to create clonal master iPSC lines. The Company’s platform is designed to overcome numerous limitations associated with the manufacture of cell therapies using patient- or donor-sourced cells. Utilizing its proprietary iPSC product platform, it is advancing off-the-shelf, multiplexed-engineered natural killer (NK) cell and T-cell product candidates which are selectively designed, incorporate novel synthetic controls of cell function. Its pipeline of iPSC-derived, chimeric antigen receptor (CAR)-targeted NK cell and T-cell product candidates include FT819, FT522, FT576, FT825, FT819, FT522, and others.
Información de la empresa
Símbolo de cotizaciónFATE
Nombre de la empresaFate Therapeutics Inc
Fecha de salida a bolsaOct 01, 2013
Director ejecutivoDr. Bahram Valamehr, Ph.D.
Número de empleados181
Tipo de seguridadOrdinary Share
Fin del año fiscalOct 01
Dirección12278 Scripps Summit Drive
CiudadSAN DIEGO
Bolsa de valoresNASDAQ Global Market Consolidated
PaísUnited States of America
Código postal92131
Teléfono18588751803
Sitio Webhttps://fatetherapeutics.com/
Símbolo de cotizaciónFATE
Fecha de salida a bolsaOct 01, 2013
Director ejecutivoDr. Bahram Valamehr, Ph.D.
Ejecutivos de la empresa
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. William H. (Bill) Rastetter, Ph.D.
Dr. William H. (Bill) Rastetter, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
617.42K
--
Dr. John D. Mendlein, J.D., Ph.D.
Dr. John D. Mendlein, J.D., Ph.D.
Independent Vice Chairman of the Board
Independent Vice Chairman of the Board
311.23K
--
Dr. Bahram Valamehr, Ph.D.
Dr. Bahram Valamehr, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
65.61K
-18.06%
Ms. Cindy R. Tahl, J.D.
Ms. Cindy R. Tahl, J.D.
Chief Legal and Compliance Officer, Corporate Secretary
Chief Legal and Compliance Officer, Corporate Secretary
58.39K
-13.40%
Dr. Robert S. (Rob) Epstein, M.D.
Dr. Robert S. (Rob) Epstein, M.D.
Independent Director
Independent Director
11.33K
--
Dr. Shefali Agarwal, M.D.
Dr. Shefali Agarwal, M.D.
Independent Director
Independent Director
10.49K
--
Dr. Karin Jooss, Ph.D.
Dr. Karin Jooss, Ph.D.
Independent Director
Independent Director
9.85K
--
Dr. Xu Yuan, Ph.D.
Dr. Xu Yuan, Ph.D.
Independent Director
Independent Director
--
--
Mr. Michael Lee
Mr. Michael Lee
Independent Director
Independent Director
--
--
Dr. Neelufar (Neely) Mozaffarian, M.D., Ph.D.
Dr. Neelufar (Neely) Mozaffarian, M.D., Ph.D.
Independent Director
Independent Director
--
--
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. William H. (Bill) Rastetter, Ph.D.
Dr. William H. (Bill) Rastetter, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
617.42K
--
Dr. John D. Mendlein, J.D., Ph.D.
Dr. John D. Mendlein, J.D., Ph.D.
Independent Vice Chairman of the Board
Independent Vice Chairman of the Board
311.23K
--
Dr. Bahram Valamehr, Ph.D.
Dr. Bahram Valamehr, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
65.61K
-18.06%
Ms. Cindy R. Tahl, J.D.
Ms. Cindy R. Tahl, J.D.
Chief Legal and Compliance Officer, Corporate Secretary
Chief Legal and Compliance Officer, Corporate Secretary
58.39K
-13.40%
Dr. Robert S. (Rob) Epstein, M.D.
Dr. Robert S. (Rob) Epstein, M.D.
Independent Director
Independent Director
11.33K
--
Dr. Shefali Agarwal, M.D.
Dr. Shefali Agarwal, M.D.
Independent Director
Independent Director
10.49K
--
Desglose de ingresos
Sin datos
Sin datos
Por negocio
Por región
Sin datos
Estadísticas de accionistas
Actualizado: sáb., 16 de ago
Actualizado: sáb., 16 de ago
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
Redmile Group, LLC
11.17%
ARK Investment Management LLC
8.94%
The Vanguard Group, Inc.
7.60%
BlackRock Institutional Trust Company, N.A.
7.47%
Citadel Advisors LLC
3.94%
Otro
60.88%
Accionistas
Accionistas
Proporción
Redmile Group, LLC
11.17%
ARK Investment Management LLC
8.94%
The Vanguard Group, Inc.
7.60%
BlackRock Institutional Trust Company, N.A.
7.47%
Citadel Advisors LLC
3.94%
Otro
60.88%
Tipos de accionistas
Accionistas
Proporción
Investment Advisor
29.67%
Investment Advisor/Hedge Fund
27.56%
Hedge Fund
11.10%
Research Firm
6.68%
Venture Capital
3.30%
Individual Investor
1.71%
Pension Fund
0.15%
Bank and Trust
0.11%
Family Office
0.10%
Otro
19.62%
Participación institucional
Actualizado: mar., 1 de jul
Actualizado: mar., 1 de jul
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q2
418
107.82M
94.06%
-31.88M
2025Q1
445
110.00M
95.96%
-29.05M
2024Q4
487
105.43M
92.56%
-50.79M
2024Q3
521
119.20M
104.73%
-42.15M
2024Q2
531
125.64M
110.45%
-29.93M
2024Q1
543
126.44M
111.19%
-6.65M
2023Q4
556
99.29M
100.70%
-34.38M
2023Q3
581
100.01M
101.45%
-44.66M
2023Q2
611
113.36M
115.11%
-33.43M
2023Q1
624
117.20M
119.39%
-6.61M
Ver más
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
Redmile Group, LLC
12.87M
11.23%
--
--
Mar 31, 2025
ARK Investment Management LLC
10.31M
9%
+10.31M
--
Mar 31, 2025
The Vanguard Group, Inc.
10.31M
8.99%
-22.58K
-0.22%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
8.39M
7.32%
-99.57K
-1.17%
Mar 31, 2025
Citadel Advisors LLC
4.29M
3.74%
-93.10K
-2.12%
Mar 31, 2025
Johnson & Johnson Innovation-JJDC, Inc.
3.38M
2.95%
--
--
Mar 31, 2025
Vestal Point Capital, LP
2.52M
2.19%
+50.85K
+2.06%
Mar 31, 2025
Baker Bros. Advisors LP
3.26M
2.84%
--
--
Mar 31, 2025
Acadian Asset Management LLC
2.47M
2.16%
+999.77K
+67.84%
Mar 31, 2025
Dimensional Fund Advisors, L.P.
2.59M
2.26%
-306.82K
-10.59%
Mar 31, 2025
Ver más
ETFs relacionados
Actualizado: mar., 2 de sep
Actualizado: mar., 2 de sep
Nombre
Proporción
WisdomTree BioRevolution Fund
0.61%
Invesco NASDAQ Future Gen 200 ETF
0.41%
iShares Micro-Cap ETF
0.03%
iShares Russell 2000 Value ETF
0.01%
ProShares Ultra Nasdaq Biotechnology
0.01%
Invesco Nasdaq Biotechnology ETF
0.01%
iShares Biotechnology ETF
0.01%
Invesco RAFI US 1500 Small-Mid ETF
0.01%
Schwab U.S. Broad Market ETF
0%
iShares Genomics Immunology and Healthcare ETF
0%
Ver más
WisdomTree BioRevolution Fund
Proporción0.61%
Invesco NASDAQ Future Gen 200 ETF
Proporción0.41%
iShares Micro-Cap ETF
Proporción0.03%
iShares Russell 2000 Value ETF
Proporción0.01%
ProShares Ultra Nasdaq Biotechnology
Proporción0.01%
Invesco Nasdaq Biotechnology ETF
Proporción0.01%
iShares Biotechnology ETF
Proporción0.01%
Invesco RAFI US 1500 Small-Mid ETF
Proporción0.01%
Schwab U.S. Broad Market ETF
Proporción0%
iShares Genomics Immunology and Healthcare ETF
Proporción0%
Dividendos
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos
División de acciones
Fecha
Tipo
Relación
Sin datos
Fecha
Tipo
Relación
Sin datos
